News

Novartis is investing a further $15 million in Israeli stem cell specialist Gamida after turning down a buyout option earlier this year.

Cancer Research UK has this morning launched its mammoth Grand Challenges cancer grants scheme, which will offer up an overall investment of £100 million to help overcome the greatest barriers to beating the disease.

The majority of healthcare professionals in the UK support greater transparency on payments received from pharmaceutical companies, but some feel the move could make working with the industry more difficult, a new survey ordered by the Association of the British Pharmaceutical Industry has revealed.

AstraZeneca is temporarily pausing two clinical trials assessing a combination of two drugs in lung cancer, after the development of lung disease in some patients.

The reach of Bristol-Myers Squibb’s Opdivo (nivolumab) is steadily increasing in the US as regulators green-light its use to treat non-squamous non-small cell lung cancer.

Lilly has bought itself worldwide rights to Locemia’s intranasal glucagon, a potential treatment for severe hypoglycaemia in people with diabetes treated with insulin, for an undisclosed amount.

NHS finances have plummeted to a shocking low as trusts rack up a deficit fast approaching £1 billion in just three months, more than the total for the whole of last year.

The National Institute for Health and Care Excellence has given its blessing for the use of Merck’s Keytruda early on in the treatment pathway for patients with advanced skin cancer.

The FDA has granted breakthrough therapy designation to Lilly’s abemaciclib, which is part of a new class of breast cancer treatments.

In a global first that could transform the treatment of multiple sclerosis, Roche’s experimental humanised monoclonal antibody ocrelizumab has shown efficacy against primary progressive multiple sclerosis, while also outperforming a popular therapy for relapsing forms of the condition.

UCB is planning to seek approval for its epilepsy drug Vimpat as a monotherapy in Europe during the first six months of next year, having bagged Phase III data supporting its use in the setting.

UK experts are questioning the use of antiviral neuraminidase inhibitors to treat seasonal or pandemic outbreaks of flu, and say carrying out randomised clinical trials to find definitive answers on this should be a “high priority” for the National Health Service.

Patients in England and Wales with opioid-induced constipation will now be able to get treatment with AstraZeneca’s Moventig on the National Health Service following the drug’s launch this week.

The crisis in general practice is having a “deep impact” on A&E services as increasing numbers of patients attend simply because they find it difficult to get a GP appointment, says a new study.

The entries are closed, and we can now reveal the finalists for the 2015 PharmaTimes Marketer and Communications Team of the Year